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The prediction of the outcome of individual patients with glioblastoma would be of great significance for monitoring responses to
therapy. We hypothesise that, although a large number of genetic-metabolic abnormalities occur upstream, there are two ‘final
common pathways’ dominating glioblastoma growth – net rates of proliferation (r) and dispersal (D). These rates can be estimated
from features of pretreatment MR images and can be applied in a mathematical model to predict tumour growth, impact of extent of
tumour resection and patient survival. Only the pre-operative gadolinium-enhanced T1-weighted (T1-Gd) and T2-weighted (T2)
volume data from 70 patients with previously untreated glioblastoma were used to derive a ratio D/r for each patient. We
developed a ‘virtual control’ for each patient with the same size tumour at the time of diagnosis, the same ratio of net invasion to
proliferation (D/r) and the same extent of resection. The median durations of survival and the shapes of the survival curves of actual
and ‘virtual’ patients subjected to biopsy or subtotal resection (STR) superimpose exactly. For those actually receiving gross total
resection (GTR), as shown by post-operative CT, the actual survival curve lies between the ‘virtual’ results predicted for 100 and
125% resection of the T1-Gd volume. The concordance between predicted (virtual) and actual survivals suggests that the
mathematical model is realistic enough to allow precise definition of the effectiveness of individualised treatments and their site(s) of
action on proliferation (r) and/or dispersal (D) of the tumour cells without knowledge of any other clinical or pathological
information.
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Gliomas are well known as extensively invasive lesions with a
variety of genetic-metabolic abnormalities that contribute to their
uncontrolled proliferation and invasion. A mathematical model
has been developed based on the two final common paths of these
mechanisms – proliferation and invasion. Serial medical imaging
can be used to track the spatio-temporal behaviour of the
detectable portion of each lesion, but the undetectable and
undefinable fraction of the neoplasm remains as a problem.
The original mathematical model (Tracqui et al, 1955), based on
the analysis of a single patient followed with serial CTs during his
final year, provided values of rates of net proliferation (r) and net
diffusion (D) that were used as averages for populations of
hypothetical patients (Woodward et al, 1996) to compare with
populations of real patients (Kreth et al, 1993) subdivided only
by extent of surgical resection, biopsy or ‘gross total resection’
(GTR). A difference in median survival of 7 weeks was predicted
mathematically, and actually found, although not statistically
significant, even with 115 patients (Kreth et al, 1993). Other
modelling efforts in the area of glioma have focused either on
multicellular spheroids in vitro (Stein et al, 2007) or on the
averages of groups of patients (Morris et al, 2006). Our
mathematical modelling approach has increasingly focused on
the individual patient, as in this study.
The current study is motivated by several other recent
applications of our modelling technique. Specifically, our discovery
that the model-predicted linear radial growth of the imaging-
detectable portion of the lesion (at a velocity dependent on both
r and D) was accurate in a population of WHO grade II gliomas
followed serially without intervening treatment (Mandonnett et al,
2003) which led to confirmation that the velocity of growth predicts
survival time in a similar population (Pallud et al, 2006). However,
since higher grade gliomas (glioblastomas) are typically treated
immediately, a similar population of serially imaged untreated
glioblastomas has been difficult to obtain and only a few cases have
been reported (Swanson and Alvord 2002; Harpold et al, 2007).
Here we demonstrate how our mathematical model, adapted to
accommodate a level of resolution of MRIs, from which could be
derived a ratio of D/r for any glioblastoma patient (Swanson, 1999;
Swanson and Alvord 2002; Swanson et al, 2002; Alvord et al, 2003;
Swanson et al, 2003a,b), can be used to help estimate the
undetectable, diffusely invading component of gliomas and to
predict survival of individual patients.
Revised 29 October 2007; accepted 6 November 2007; published online
4 December 2007
*Correspondence: Dr KR Swanson, Laboratory of Neuropathology,
Department of Pathology, University of Washington, Box 359791,
Harborview Medical Center, 325 9th Avenue, Seattle, WA 98104-2499,
USA; E-mail: swanson@amath.washington.edu
British Journal of Cancer (2008) 98, 113–119
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sIt should be emphasised that the model uses only currently
available diagnostic pre-operative MR imaging characteristics of
individual patients, the only necessary requirement being the
presence of contrast enhancement, and uses no other clinical or
statistical interpretation, not even the histologic diagnosis of
glioblastoma (although all of the present patients have such a
diagnosis). It should also be emphasised that model parameters
D and r are net, downstream from any intracellular metabolic
activity controlling migration and proliferation, irrespective also of
any microenvironmental factors that might further modify them.
In contrast to the original comparison of virtual and real patients
(Woodward et al, 1996), where individual sizes were not known
and where averages from the scanty literature were available at the
time of diagnosis (Blankenberg et al, 1995) and at death
(Concannon et al, 1960; Burger et al, 1988) had to be used, the
present series was able to use not only the individual sizes known
for each patient at diagnosis, but also the confirmation of the
completeness of resections by post-operative enhanced CT, not
just the surgeon’s opinion (Kreth et al, 1993). The results suggest
the potential utility of such modelling (avoiding all statistically
defined qualifiers, including age, Karnofsky Performance Score
(KPS), histological type and grade, etc.) in future clinical studies
comparing specific biomarkers and treatments of gliomas in
individual patients.
MATERIALS AND METHODS
The patients
The 70 patients were adults (22–79 years old, mean age 58 years)
with supra-tentorial glioblastoma diagnosed, treated and followed
at the University of Washington Medical Center in 1993–1995.
Follow-up was complete to death in 66 patients and to 104, 208,
230 and 230 weeks in the 4 patients who were lost to follow-up. All
of the patients received X-irradiation to the tumour of 59.4Gy or
more, 58 received chemotherapy and 30s operations. Our
Institutional Review Board approved this retrospective study of
patients.
Of the 70 patients, 58 had lobar tumours and 12 had tumours in
deep or mixed location; 58 had tumours that anatomically made
them eligible for ‘gross total resection’ (GTR), but 20 of these were
reclassified as only ‘subtotal resection’ (STR) when post-operative
enhanced CT revealed a nodule of residual tumour. Of the 18
whose tumours were too extensive even to consider GTR, 11 had
STR and 7 only biopsy. Major clinical characteristics are
summarised in Figure 1, which shows the durations of survival
following the specific treatments correlated (Po0.01 Student’s
t-test) with age and KPS and demonstrates the broad ranges of
clinical factors that can be accommodated by – but not
incorporated in – the mathematical model.
The diagnosis of glioblastoma was generally the result of a
consensus of four neuropathologists at a time when one of the
present authors (ECA) was chief of neuropathology and required
necrosis (Nelson et al, 1983) as one of the histologic criteria of
glioblastomas. No distinction was made between various subtypes,
including primary or secondary, as later suggested by Kleihues
et al (2002).
We used the pre-operative tumour volumes as defined by
gadolinium-enhanced T1-weighted (T1-Gd) and T2-weighted (T2)
MR imaging. These volumes had been digitised and calculated
using NIH Image software that added the areas on each slice and
multiplied the sum by the thickness of each section to obtain the
volume. Two independent observers had made the measurements
and the mean was accepted. The percent differences between the
two observers was 7.6% (±7.3%) and 6.0% (±4.7%) for T1-Gd
and T2 measurements, respectively. The total volumes included
any central necrosis. From these volumes we calculated the radii of
equivalent spheres (Figure 2), and these radii were the only data
entered into the mathematical formulations.
We used other clinical data only to define appropriate subsets to
be compared as to durations of survival, actual vs predicted
(virtual). These data included statements as to whether the patient
had received steroids, what type of surgery had been performed,
and the duration of survival from the date of operation. The
extents of resection included only statements as to biopsy only,
subtotal and gross total resection, the latter two arbitrarily defined
by the presence or absence of residual tumour on post-operative
contrast-enhanced CT, performed within 2 days following surgery.
Model development
The mathematical model continues to be based purely on the
classical definition of cancer as uncontrolled proliferation of cells
with the potential for invasion and metastasis, simplified for
gliomas, which practically do not metastasise. Thus, the model
defines the behaviour of gliomas in words and mathematics as
follows:
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This is a classical conservation–diffusion equation (Murray,
2003), in which c(x, t) defines the concentration of malignant cells
at location x and time t, D (mm
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 1) is the random motility
(dispersal) coefficient defining the net rate of migration of the
tumour cells, r ( per day) represents the net proliferation rate of
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Figure 1 Scatter graphs defining some of the major characteristics of the
70 patients with correlations of duration of survival for BX/STR patients
(asterisks) and for the GTR patients (squares) with age, KPS and KPS-age.
Note the broad ranges, illustrating the variety of the patients. Note also
that none of these data enter into the mathematical model.
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sconcentration of cells that a volume of tissue can hold (i.e., the
carrying capacity of the tissue) and r
2 represents the dispersal
operator, the Laplacian, expressed mathematically as the sum of
three second derivatives in space (Strang, 1991). The model has
been adapted to use the BrainWeb Atlas (Collins et al, 1998) to
accommodate an irregularly shaped tumour located anywhere
within 3-dimensionally continuous heterogeneous tissue with
differences in grey and white matter, anatomically accurate to
1mm
3 (Swanson, 1999; Swanson et al, 2003a). The model can
accommodate different velocities of glioma cell motility in grey
and white matter (Swanson, 1999) but, since the original MRIs
were not available, this feature was not used in the present
analysis.
Equation (1) implies mathematically that the ‘edge’ of the visible
tumour advances asymptotically as a ‘traveling wave,’ (Swanson,
1999) which expands radially and linearly, according to Fisher’s
approximation or Skellam’s model (Shigesada and Kawasaki,
1997): v ¼ 2
ﬃﬃﬃﬃﬃﬃ
rD
p
. Although there is no true edge to an infiltrating
tumour, such as a glioma, any point on the ‘gradient’ between the
T1-Gd and T2 circumferences (Figure 3) moves as part of the
‘traveling wave.’ In general, as shown schematically in Figure 3,
proliferation (r) tends to drive the wave up (but not above the
carrying capacity K) and dispersal (D) tends to drive the gradient
centrifugally.
The ‘gradient’ between the T1-Gd and T2 images can be
expressed in a different way, involving the ratio D/r. This ‘gradient’
has not been quantitatively defined but can be approximated from
the observations of Kelly et al (1987), Kelly (1993) and Dalrymple
et al (1994), who reported that the T1-Gd circumference
approximates the edge of the ‘solid tumour’ and that the T2
circumference represents not only the extent of oedema but also a
zone of a low concentration of ‘isolated tumour cells.’ We
hypothesised that these circumferences might represent concentra-
tions of tumour cells equal to 80 and 16%, respectively, of the
maximum concentration (Figure 3). That tumour cells extend much
farther then even the imageable abnormality is evidenced by
malignant cells being cultured by Silbergeld and Chicoine (1997)
from as far away as 4cm. A close study of other solutions of the
model Eq. (1) finds a highly non-linear relationship between the
ratio D/r and the average radii of spheres equivalent to the volumes
defined by T1-Gd and T2, rT1 and rT2, respectively (Harpold et al,
2007). The equation by no means is a simple ratio of any part(s)
of the MR images, but includes fractional exponents of ratios of
differences that make it highly non-linear.
Our model consists of the following two parts: (1) Eq. 1, the
spatio-temporal bio-mathematical formulation of the proliferation
and dispersal of the tumour cells, both visible (detectable by scans)
and invisible (diffusing into the surrounding normal-appearing
tissue), and (2) the use of Fisher’s approximation (v ¼ 2
ﬃﬃﬃﬃﬃﬃ
rD
p
)t o
estimate the time required for the tumour to expand from its
detectable actual size at diagnosis to its size at death (Woodward
et al, 1996).
Data analysis
Statistical analysis was performed (SPLUS, 1998), as noted
throughout the text. From the pre-operative MRI volumes, we
calculated the average radii of equivalent spheres of the T1-Gd and
T2 volumes for each of the 70 patients (Figure 2). These became
the actual data from which all of the rest of the calculations derive
(see Results section). The mean T1-Gd radius was 2.01cm,
the median 2.13cm and the range from 0.86 to 3.26cm. The mean
T2-weighted radius was 2.89cm, the median 2.84cm, and the range
from 1.05 to 4.75cm.
We used other clinical data provided to classify each actual
patient according to the extent of resection. We found that there is
no statistically significant difference between the means of the T1-
Gd radii of the 7 biopsy patients (2.03cm) and the 31 STR patients
(2.20cm, P¼0.43) or of the 7 biopsy and 32 GTR patients (1.81cm,
P¼0.44), in large part because of the small number of biopsy
patients (N¼7); but there is a significant difference between the
means of the T1-Gd radii of the combined 38 biopsy and STR
patients (mean¼2.17cm) and the 32 GTR patients (P¼0.01 using
Student’s t-test). Justification for this combination of patients is
provided in the Results section.
From the diagnostic MRI tumour volumes, we have also
calculated the actual ratio, D/r, for each of the 70 patients and
found the median to be 9.83mm
2, the mean 10.52mm
2 and the
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Figure 2 The actual data used for the present analysis: average radii of
spheres equivalent to the T1-Gd and T2-weighted MRI volumes for
glioblastomas of 70 actual patients subjected to biopsy or subtotal
resection (BX/STR, asterisks, N¼38), or to gross total resection (GTR,
squares, N¼32) as defined by the absence of tumour on post-operative
enhanced CT.
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Figure 3 Schematic representations of the relationships between T1-Gd
and T2 images and the concentrations of tumour cells and of the effects of
increasing the net rates of diffusion (D) and proliferation (r) on the
‘traveling wave’ of the ‘edge’ of an enlarging glioblastoma. The thresholds of
detection for T1-Gd and T2 MR images (solid lines) are estimated at 80
and 16%, respectively, of the maximum cell density K in Equation (1).
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srange from 0.24 to 35.92mm
2. There is no significant difference in
the distributions of the ratio D/r between actual patients who had
had steroids for a few days (N¼22) and those who had not had
steroid (N¼45) before their MRIs (Figure 4A, P¼0.75 by
Kolmogorov-Smirnov’s test (K-S test)), Watling et al, (1994)
having used steroids for a longer time to see any effect. There is
also no difference in the distributions of the ratio D/r for the
actual biopsy, STR and GTR patients (Figure 4B, K-S test
P¼0.675).
In the absence of a second set of MRIs to define the actual velocity
for each patient, we had to resort to estimates, applying the average
r of 0.012 per day (Tracqui et al, 1995; Woodward et al, 1996) to the
calculated actual ratios of D/r to estimate D for each actual patient.
We could then apply Fisher’s approximation (v ¼ 2
ﬃﬃﬃﬃﬃﬃ
rD
p
)t o
calculate an approximate radial velocity of expansion of the ‘edge’
of each tumour. We found the median velocity to be 0.075
mmday
 1, the mean to be 0.0723mmday
 1, and the range from
0.0118 to 0.1438mmday
 1. Since the ratio of D/r is known from the
MRIs of each patient, any different value of r would induce a
corresponding change not only in this estimated value of D but also
in the velocity v. We accepted the average size at death as equivalent
to a sphere of radius 3cm (Woodward et al, 1996) and allowed the
model to project each tumour at its estimated velocity v and to
determine the time required to grow from its actual diagnostic T1-
Gd radius to the assumed fatal radius of 3cm. These times were the
predicted virtual durations of survival, which could be calculated
not only without treatment but also by superimposing virtual
resections of any extent desired. Any or all of these predicted
survival times could be compared with the appropriately matched
actual durations of survival (see Results section).
Estimates of the predicted survival time for each of the 70
patients were made following a variety of ‘virtual’ treatments: (1)
biopsy only (no resection) and STR (treated as no resection, as in
Woodward et al, 1996), (2) resection of 100% of the T1-Gd volume
(the smallest ‘virtual GTR’ that could have accomplished the
CT-proven result) and (3) resection of 125% of the T1-Gd volume
(an arbitrarily chosen estimate of a more extensive ‘virtual GTR’
that the surgeon could have easily undertaken). Groups 2 and 3
were predicted to develop a range of predictions for comparison
with the actual GTR patients, in this data set defined by the
absence of residual tumour on post-operative enhanced CT. It
seems obvious that the exact extent of resection beyond complete
removal of the CT-enhancing tumour was not determined in any
actual patient and was not likely to have been the same in each
patient. Virtual resection was simulated, as by Swanson et al
(2003a), by imposing a cell concentration of zero in the resected
region and allowing the computer to proceed with the model-
predicted tumour growth defined by Eq. (1).
RESULTS
We begin by presenting Figure 5, summarising the actual
durations of survival for the 7 patients subjected to biopsy only,
the 31 patients subjected to STR and the 32 patients subjected to
GTR as defined by post-operative enhanced CT. Since there were
so few biopsy patients and since there was no difference in actual
durations of survival compared with the STR patients (P¼0.671,
w
2-test), consistent with previous studies of patients receiving Bx
or STR (Lacroix et al, 2001) these two actual groups were
combined in further comparisons. These actual results (Figure 5)
are meaningless until matched with appropriate controls (see
Figure 6 below).
In Figure 6, we have paired the virtual and real patients for
appropriate comparisons. It should be noted that these comp-
arisons are being made between real and virtual patients with
exactly the same pre-operative MRI characteristics defined by the
actual size (T1-Gd volume) and the actual ratio D/r (derived non-
linearly from the actual T1-Gd and T2 volumes). The actual
survival curves are represented as asterisks and the virtual survival
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Figure 5 Actual survival curves for 7 patients subjected to biopsy (BX,
pluses), for 31 subjected to subtotal resection (STR, triangles) and for 32
subjected to gross total resection (GTR, asterisks) as defined by presence
or absence of residual tumour on post-operative enhanced CT. Inset shows
a close-up of the survival curves near the median survival times of 36.5 and
62 weeks, respectively.
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Figure 4 Distributions (%) of actual values of D/r,i n( A) for 22 patients
having had steroid (asterisks) and for 45 patients not having had steroid
(circles) before their MRIs, and in (B) for 38 patients having had biopsy or
subtotal resection (circles) and 32 patients having had gross total resection
(asterisks), as defined by the presence or absence of residual tumour in
post-operative enhanced CT.
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scurves as open boxes of various shapes corresponding to the
various extents of resection. Although the degree of overlap
represents the degree of accuracy of prediction, enlargements are
provided in the insets to reveal the slight discrepancies present. In
Figure 6A, the untreated virtual patients are compared with the
actual patients subjected to biopsy and STR. The curves are
practically identical (no significant difference P¼0.693, w
2-test), as
predicted by Woodward et al (1996) and as found by Lacroix et al
(2001). In Figure 6B, the untreated and treated virtual (100 and
125% resections, respectively) and actual patients subjected to
GTR are compared. As expected, the actual curve lies between the
100 and 125% ‘virtual’ resections. Neither of the virtual curves was
significantly different from the actual (P¼0.695, 0.685, respec-
tively, w
2-test).
DISCUSSION
The real power of any model is its ability to provide meaningful
predictions (Murray, 2003), as seen most graphically in Figure 6.
The present mathematical model, although requiring a computer
for solutions, is relatively simple and based biologically on the
classical definition of cancer/gliomas. It reduces the significant
variables to only two, the ‘final common paths’ of net proliferation
(r) and dispersal (D) rates. All of the genetic-metabolic
abnormalities that are being revealed to underlie the mysteries of
glioblastomas lie upstream but their downstream net effects can
be quantified by the model. The model has allowed us to provide
almost exact virtual controls, matched for pre-operative size
(T1-Gd) and D/r, untreated and treated, for each patient, and to
make accurate predictions of survival times following a broad
range of surgical resections, as shown in Figure 6. As Woodward
et al (1996) predicted mathematically and as shown actually in
Figure 5, there is no difference in duration of survival between real
patients receiving biopsy only and those receiving STR (P¼0.671,
w
2-test). As for the evaluation of the effectiveness of GTR, a subject
of almost limitless controversy (Nazzaro and Neuwelt, 1990; Kelly,
1993; Kreth et al, 1993, 1999; Kowalczuk et al, 1997; Hess, 1999;
Keles et al, 1999; Lacroix et al, 2001), we would emphasise Figure 6,
where the virtual ‘untreated’ controls (asterisks) for each subset
(biopsy/STR and GTR) differ in duration of survival (32.4 vs 44.9
weeks). There being no difference in the distributions of the actual
ratios D/r (Figure 4B), the only remaining reason for these
differences in survival is that the individually matched T1-Gd sizes
differ for the two subsets, as can also be seen in Figure 2. Both
Figure 2 and Figure 6 suggest that the ‘better’ patients were chosen
for GTR.
Thus, comparisons between the real (unmatched) subsets
(Figure 5) are, in our opinion, not so appropriate as comparisons
between the real and virtual pairs of matched subsets (Figure 6).
We conclude that the 25.5 weeks advantage that actually GTR
appears to provide over the actual (but unmatched) BX/STR
controls (62 vs 36.5 weeks in Figure 5) can be shown by the present
mathematical model to be half-accounted for by the inadvertent
selection of many patients with smaller tumours to be subjected to
GTR (c.f., Figure 2). If one compares the real GTR patients with
their virtual controls matched by pre-operative imaging char-
acteristics (Figure 6B), one can see that the advantage is only about
17.1 weeks, this being the difference between the median survival
times of the actual 32 patients (62 weeks) and their 32 model-
matched (biopsy only) virtual controls (44.9 weeks). A comparison
of the two sets of virtual controls shows that those for the GTR
patients survived 12.5 weeks longer than for the BX/STR patients
(median¼44.9 weeks in Figure 6B vs 32.4 weeks for Figure 6A).
Clearly, the ‘better’ patients were chosen for GTR.
We believe that the present mathematical model is a powerful
tool for understanding and interpreting the images displayed by
different MR imaging sequences of glioblastomas since it success-
fully combines two of the pre-operative imaging characteristics of a
glioblastoma, the ‘size’ and the ‘gradient’ of concentration of glioma
cells between the ‘edges’ revealed by T1-Gd and T2 weightings of
the MRI (Kelly et al, 1987; Dalrymple et al, 1994). A significant part
of the power of the model is the use of the actual sizes shown in the
MRIs (Figure 2). The prognostic importance of the ‘size’ has also
been controversial, a few (Yamada et al, 1993; Xue and Albright,
1999; Jeremic et al, 2004) reporting it to be significant but most
(Reeves and Marks, 1979; Andreou et al, 1983; Wood et al, 1988;
Hammoud et al, 1996; Kowalczuk et al, 1997; Keles et al, 1999;
Kreth et al, 1999; Lacroix et al, 2001) failing to find any relation.
Xue and Albright (1999) make the point that the volume should be
calculated as accurately as possible (i.e., planimetrically as the sum
of the areas), as we have done, not modelled simply as spheres or
ellipsoids with only the diameter(s) measured. The failures are easy
to understand because of the biologic heterogeneity of all groups of
patients so far studied, that is, with inherently different but
unknowable rates of proliferation and invasion. These biologically
fundamental rates have been subsumed within the histopathologic
diagnosis (e.g., ‘generally circumscribed, slowly growing,’ ‘slow
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Figure 6 (A) Survival curves for actual patients (asterisks) and virtual
patients (squares) subjected to biopsy or subtotal resection (BX/STR,
N¼38). Inset shows a close-up of the survival curves near the median
survival times of 32.4 and 36.5 weeks. (B) Survival curves on a longer time
scaling following gross total resection (GTR, N¼32) in actual patients
(asterisks) defined by the absence of residual tumour on post-operative
enhanced CT. The virtual patients (matched to actual pre-operative T1-Gd
volume and D/r ratio derived from the T1-Gd and T2 volumes) were
subjected to no resection (BX/STR, squares), to resection of 100% of the
T1-Gd volumes or radii, rT1 (circles) and to resection of 125% of the T1-Gd
volumes or radii, 1.25 rT1 (diamonds). Inset shows a close-up of the survival
curves near the median survival times of 44.9, 55, 62 and 66.9 weeks.
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sgrowth, and diffuse infiltration,’ ‘rapid, infiltrative growth’ etc.)
(Kleihues et al, 2002) and have previously not been more
specifically considered, much less estimated. In fact, these turn
out to be the most significant of all of the factors, even better than
age and KPS. It is not surprising that such previously unidentified
phenotypical diversity would be impossible to control for using
standard statistical analysis of groups of patients without the
advantage of a mathematical model to characterise virtual controls
for each individual patient, untreated or subjected to various
extents of resection.
Another reason for previous failures (Reeves and Marks, 1979;
Andreou et al, 1983; Wood et al, 1988; Kreth et al, 1993; Hammoud
et al, 1996; Keles et al, 1999; Lacroix et al, 2001) to find an effect of
‘size’ of the tumour relates to the inherent ambiguity of any ratio;
that is, the ratio D/r can remain the same if both D and r change in
the same direction. Furthermore, statistical techniques generally
look for linear relationships, whereas the relationship we have
found for D/r, which we have associated with the T1-Gd and T2
radii, is highly non-linear.
These ambiguities and complexities relate to the invisible
infiltration (dispersal) of glioma cells. At one theoretical extreme,
for example, if there had been no dispersal, both the volume and
the radius of the solid tumour could have increased exponentially
with time, as postulated by Blankenberg et al (1995) and Haney
et al (2001). With dispersal, however, the infiltrating cells become
invisible and represent an unknowable fraction of the total, leaving
the mass of those cells that remain visible (the complementary but
still unknowable fraction of the total) to appear to grow quite
differently: the radius actually increases linearly with time
(according to Fisher’s approximation) and the volume as a cubic.
Neither radius nor volume increases exponentially as the classical
model with a constant volume-doubling time demands. This is
mathematically true even though the total number of tumour cells,
both visible and invisible, may continue to increase exponentially.
The measurable difference between exponential and cubic growth
is relatively slight over the time intervals typically available
clinically, but the consequences for longer term predictions are
quite marked. The concept may be subtle but the effect is real and
important. For another example, the ‘volume-doubling time’ that
can be calculated at any moment in our model is not constant but
decreases continuously, as actually shown in the report by Haney
et al (2001). The concept of a volume-doubling time is meaningless
for infiltrating tumours such as gliomas.
Evidence that T2 reveals not just oedema is seen in Figure 4,
where the distribution of the values of D/r is the same whether
steroid had been given or not. Of course, the short duration of
administration of steroid in these patients may not have allowed
any significant decrease in the T2 image (Watling et al, 1994). The
evidence in Figure 4 suggests that the postulated difference
between the hypothesised concentrations of tumour cells visua-
lised by T1-Gd (80% of maximum) and T2 (16% of maximum)
images may be very close to true, even though the reports of Kelly
et al (1987), Kelly (1993) and Dalrymple et al (1994) were
quantitatively far from convincing.
CONCLUSIONS
Our mathematical model rests on only two biological factors, the
net rates of proliferation (r) and diffusion (D), which are the ‘final
common paths’ controlling cancerous growth. The comparison of
the virtual results predicted by this mathematical model with the
real results of 70 patients has revealed the power of the model as a
‘proof of principle’ not only in predicting durations of survival
following a wide range of resections but also in accommodating the
actual size of each patient’s glioblastoma and the estimated
‘gradient’ of cells migrating from the ‘edge’ of the tumour. A major
deficiency of the present report is the absence of a second MRI
before treatment, forcing us to use the average r of 0.012 per day
(Tracqui et al, 1995) to calculate an approximate D and an
approximate velocity of expansion for each patient. To paraphrase
Archimedes’ request for a fulcrum and a strong lever, given a
second MRI without intervening treatment, the model would have
allowed measurement of the actual velocity (v) and calculation of
actual rates of dispersal (D) and proliferation (r) for each actual
patient and the direct calculation of their matched virtual controls
without all of the approximations that we had to resort to. With
that information we should also be able to determine not only the
degree of effectiveness of each patient’s individualised therapies
but also of the specificity of each therapy for affecting some step in
the intricate metabolic pathways controlling D and/or r. Although
we could not calculate D and r explicitly for each of the patients,
the ratio D/r fell within the range expected for glioblastomas. We
also need more data concerning the size at death, attainable by late
follow-up MRI and autopsy, to define more accurately the end
point, the postulated ‘fatal tumour burden.’
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